Editorial introductions

doi:10.1097/aci.0000000000000239

Home
Search
Editorial introductions

Open Access
https://doi.org/10.1097/aci.0000000000000239

Editorial introductions

Feb 1, 2016
Current Opinion in Allergy & Clinical Immunology

Listen

Abstract
Literature Map
Similar Papers

Abstract

Current Opinion in Allergy and Clinical Immunology was launched in 2001. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of allergy and clinical immunology are divided into 14 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Editors and Section Editors for this issue. EDITORS Mark BallowMark BallowDr Mark Ballow received his MD from the University of Chicago Pritzker School of Medicine, USA. After a pediatric residency at Yale-New Haven Hospital, USA, he completed an immunology fellowship at the University of Minnesota Hospitals, USA. He was the Chief of Clinical and Experimental Immunology at Walter Reed Army Medical Center, USA. He was then appointed as Chief of the Division of Clinical Immunology in the Department of Pediatrics at the University of Connecticut, USA from 1975 to 1988, and became Chief of the Division of Allergy/Clinical Immunology and Pediatric Rheumatology, and Program Director of the Allergy/Immunology fellowship program at The Women and Children's Hospital of Buffalo, State University of New York at Buffalo, USA from 1988 to 2012. He is presently Training Program Director of the Allergy/Immunology Fellowship program at University of South Florida, Allergy & Immunology Division at All Children's Hospital in St Petersburg, FL. Dr Ballow is certified by the American Board of Pediatrics, American Board of Allergy & Immunology (ABAI), and in Clinical Laboratory Immunology. He was on the Board of Directors of the ABAI from 1992–1998. He has served on four editorial boards including the Journal of Allergy and Clinical Immunology (1984–1989; 1995–2000), and is an Ad Hoc reviewer for a number of pediatric, allergy and immunology journals. He has recently been appointed to the editorial board of Journal of Allergy and Clinical Immunology: In Practice. Dr Ballow has served as an ad hoc member of several NIH study sections, and was a member of the committee that published the first Allergy and Immunology Medical Knowledge Self Assessment Program (MK-SAP), and was a member of the new 3rd edition AI-MK-SAP. Dr Ballow is a Fellow of the American Academy of Asthma, Allergy and Immunology, and has served on the Board of Directors of the Academy (1996–1999), and has chaired the A/I Training Program Directors, Basic Clinical immunology Interest Section, and the Post-graduate Education Program. He was President of the American Academy of Allergy, Asthma and Immunology in 2010–2011. Dr Ballow is a member of the Clinical Immunology Society, the Florida Allergy Society, and the American College of Allergy, Asthma and Immunology. He also has served on the Blood Product Advisory Committee of the FDA. Dr Ballow's major clinical interests include chronic sinusitis, primary immune deficiency disorders, and the uses and mechanisms of action of Intravenous Immune Globulin (IGIV). His research interests include the immunology of the newborn infant and the immunoregulatory effects of IVIG, Vitamin A and retinoic acid. G. Walter CanonicaG. Walter CanonicaProfessor Giorgio Walter Canonica is Director of the Allergy & Respiratory Diseases Clinic, Genoa University, Italy, a GALEN Centre of Excellence. Professor Canonica first specialised in pulmonary diseases after having received his medical degree from the University of Genoa, Italy. He then specialised in Allergy and Clinical Immunology at Florence University, Italy. He subsequently conducted clinical immunology and allergology research in several European universities and institutes, in addition to two years at the Medical University of South Carolina, USA. Since returning to the University of Genoa in 1995, Professor Canonica has held a number of academic positions including Director of the Speciality School of Allergy and Clinical Immunology, Director of the Specialty School of Pulmonary Diseases and Chairman of Chairman of the Dept of Medical Specialties (University Hospital S. Martino Genoa, Italy). He is Board Member of ARIA (Allergic Rhinitis and its impact Asthma) guidelines) and GALEN (Global Allergy and Asthma European Network). Professor Canonica's research interests include examination of the molecular events and interactions between immunocompetent cells, inflammatory cells and epithelial cells in allergic inflammation and airway remodelling. He is particularly involved in new strategies in the treatment of allergic disease, including biological response modifiers, such as specific immunotherapy (with a special focus on SLIT – sublingual immunotherapy - and Severe Asthma treatment with biologics). Professor Canonica has published extensively in international journals and acts as a referee of many immunology journals. In addition, Professor Canonica is a member of a number of societies, he was President of World Allergy Organization 2008/09. He is also currently President of Global Asthma Association - Interasma. He was President of SIMeR (Italian Society of Respiratory Medicine) 2000–2003 and he is Honorary President of this same Society since 2007. He is currently President of SIAAIC Italian Society of Allergy, Asthma and Clinical Immunology (2014–2017). SECTION EDITORS Ruby PawankarRuby PawankarProf. Ruby Pawankar MD, PhD, FRCP (UK), FAAAAI is currently the Immediate Past President of the World Allergy Organization (WAO) and was WAO President from January 2012 to December 2013, after serving as a member of the Board of Directors since 2001, as Treasurer 2008–2009 and as President-Elect 2010–2011. She is currently also the President of the Indian Academy of Allergy. She is Professor of Allergy in the Department of Pediatrics at Nippon Medical School, Tokyo, Japan, and Guest Professor at the Kyung Hee University School of Medicine in Seoul, Korea and the Showa University School of Medicine in Tokyo, Japan. After graduating in medicine from the Armed Forces Medical College, Pune, India, Prof. Pawankar did her residency and post-graduation from BJ Medical College, Pune, India. Thereafter, she trained in Allergy & Clinical Immunology at the Nippon Medical School and Juntendo University School of Medicine in Tokyo, Japan from where she obtained her doctorate. Prof. Pawankar serves on numerous committees and boards of many academic organizations and grant reviews, is a Member/Fellow of organizations including the Collegium International Allergolicum, the American Academy of Allergy, Asthma and Immunology, the American College of Allergy and Immunology, the European Academy of Allergy and Clinical Immunology and the Japanese Society of Allergology. She has delivered several orations/named lectures nationally and internationally including the SK Malik Oration and DN Shivpuri Oration. She is a recipient of many academic awards including the World Achievement Award in Allergy from Thailand; the International Distinguished Fellow Award from the American College of Allergy, Asthma & Immunology; and especially the Pravasi Bharatiya Samman Award from the President of India for excellence in medicine. Prof. Pawankar's research has focused on the cellular and molecular mechanisms of allergy, immune cells like mast cells and T cells, epithelial cell-immune cell interactions, novel roles of IgE, mast cell-IgE cascade, environmental pollution, immunotherapy and novel therapies for respiratory allergies. In 1995, she was the first to report on the increased presence and role of gamma delta T cells in allergic rhinitis. In 1997, she was among the first to show that mast cells in perennial allergic rhinitis exhibit increased expression of the IgE receptor as well as being a major source of the obligatory pro- allergic Th2 cytokines interleukin IL-4, and IL-13 capable of driving local allergen-specific IgE synthesis by B lymphocytes and has formed the basis of the successful therapeutic targeting of these cytokines with biological therapeutics. Her research and educational activities have been strongly translational as it applies to clinical science. This has resulted in 411 publications including peer-reviewed original articles in: Journal of Allergy and Clinical Immunology, Journal of Clinical Investigation, Journal of Immunology, Blood, American Journal of Respiratory and Critical Care Medicine, Allergy, Clinical & Experimental Allergy, International Archives of Allergy and Immunology, Current Opinion in Allergy and Clinical Immunology etc, and invited reviews and book chapters. She is an Editor/ Associate Editor of peer-reviewed journals such as: International Archives of Allergy, Clinical Experimental Immunology, Current Opinion in Allergy and Clinical Immunology etc., and books including the 6 volume book ‘Allergy Frontiers’, the WAO White Book on Allergy, Update on Respiratory Disorders, and is a co-author of several consensus documents. She has mentored over 30 fellows from Japan and abroad. Prof. Pawankar has chaired as President and organized several international congresses including: the 10th Trans Pacific Allergy Congress in Mumbai, India; the first and the Middle East Allergy Congress, in 2009 and 2011 respectively; the WAO International Scientific Conference (WISC) 2012, India; the World Allergy Asthma Congress 2013, Milan, Italy, as well as several educational programs and has been a visiting faculty to lecture at several institutions such as Harvard Medical School, USA; the University of Wisconsin, USA; Imperial College, London, UK; Catholic University, Argentina; the University of Sao Paolo, Brazil and Mahidol University, Thailand. At an organizational level, her vision is to create a channel of dialogue with all stakeholders to address the unmet global public health issue of asthma and allergies in the context of non-communicable diseases (NCDs) via an integrated approach that could lead to increased resources for research, improved patient care, better health care delivery, and preventative strategies. David P. SkonerDavid P. SkonerDr David P. Skoner is Director of the Division of Allergy, Asthma, and Immunology in the Department of Medicine of Allegheny General Hospital in Pittsburgh, Pennsylvania, USA. He is also Professor of Medicine at the Temple University School of Medicine in Philadelphia, Pennsylvania, USA and Clinical Professor of Pediatrics, West Virginia University School of Medicine, USA. Previously, he was Associate Professor of Pediatrics and Otolaryngology at the University of Pittsburgh, School of Medicine, USA and has served as the Chief of the Section of Allergy/Immunology and Director of the Allergy and Immunology Training Program at the Children's Hospital of Pittsburgh, USA. Dr Skoner received his BS degree from Juniata College in Huntingdon, Pennsylvania, USA and his MD degree from Temple University in Philadelphia, Pennsylvania, USA. He served his residency in general pediatrics at Children's Hospital in Cincinnati, Ohio, USA, and he completed his fellowship in allergy/immunology at Children's Hospital in Pittsburgh. His current research interests include the relationships between respiratory viruses, asthma, immunity, and stress; the relationship between viral and allergen-induced nasal inflammation and middle ear disease; and the efficacy and safety (HPA axis function and growth in children) of inhaled and intranasal steroids. Dr Skoner has received NIH funding and written more than 100 articles and given more than 200 presentations on respiratory disease. His articles and abstracts have been published in many leading journals, including Pediatrics, Journal of Allergy and Clinical Immunology, Pediatric Research, American Journal of Respiratory and Critical Care Medicine, The Journal of the American Medical Association, and American Review of Respiratory Disease. Dr Skoner serves on the editorial advisory boards of the journals Current Allergy and Asthma Reports, and Current Opinion in Allergy and Clinical Immunology, and previously served on the editorial board of the American Journal of Rhinology. He is a Fellow of the American Academy of Pediatrics and a member of the Society of Pediatric Research, the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma & Immunology, the Association for Research in Otolaryngology, and the American Pediatric Society. He has been recognized as one of America's ‘Top Doctors’ (Pediatric Allergy & Immunology, Castle Connolly Medical Ltd.) from 2001 to 2014, as one of the Most Influential Doctors by USA TODAY (http://www.usatoday.com/yourlife/health/most-influential-doctors.htm), and as a U.S. News Top Doctor (www.usnews.com/top-doctors). He was invited to join the Best Pharmaceuticals for Children Act (BPCA) Pediatric Asthma Therapeutics Group convened by the National Institute of Child Health and Human Development. Dr Skoner co-founded the Nemacolin Asthma Conference (www.ahn.org/nemacolin-asthma), a continuing medical education (CME) program that attracts a national and an international audience and faculty, now in its ninth year. He also founded and is the President of ‘For Your Good Health’ (www.fygh.org), a Pennsylvania non-profit corporation that brings together asthma stakeholders in the development and implementation of state-of the-art programs to educate children with asthma and their caregivers about the disease and its management. The aim of these programs is to reduce asthma's impact on patients, caregivers, the community, and the healthcare system by helping the patients to lead near-normal lives. He also serves on the board of the non-profit Greater Pittsburgh Allergy Asthma and Immunology Society (GPAAIS), which serves to educate and inform physicians and other health care providers. Dr Skoner was selected as a finalist in the category of ‘Health Care Provider: Physician’ for the 2013 Pittsburgh Business Times Health Care Heroes Awards. J. Andrew GrantJ. Andrew GrantDr Grant is a native of Florida and received his undergraduate degree from Harvard University, USA, in biochemical sciences. After attending Duke Medical School, USA, he did a residency in internal medicine at New York Hospital – Cornell Medical Center in New York City, USA. He did a fellowship in immunology with Leroy Hood at the National Institutes of Health and an allergy-immunology clinical fellowship at Johns Hopkins University, USA, with Phillip Norman and Lawrence Lichtenstein. In 1973, he established the first basic and clinical research program in allergy in Texas at the University of Texas Medical Branch in Galveston, USA. Presently he is Clinical Professor in the Departments of Medicine and Microbiology-Immunology and training program Director in Allergy-Immunology at that institution. He has served as Division Director and Vice Chair for Research within the Department of Internal Medicine. He vacations during the summer months in Colorado and has been appointed Clinical Professor at University of Colorado Medical School, USA. Dr Grant has been an active member of the American Academy of Allergy, Asthma and Immunology for over four decades. His contributions to this organization include chairing the Program Directors Assembly, Mechanisms of Allergy Interest Section, Postgraduate Education Committee, Scientific Workshops and Exhibits Committee, and Immunotherapy Committee. He served on the Editorial Board of the Journal of Allergy and Clinical Immunology. He founded In-training Examination for Allergy-Immunology postdoctoral fellows, the first subspecialty exam of its type. Dr Grant served as President of the Texas Allergy Asthma and Immunology Society and a Director of the American Board of Allergy and Immunology, and a member of the Residency Review Committee for Allergy and Immunology. He chaired the Pulmonary Allergy Drugs Advisory Committee of the Food and Drugs Administration and currently is a member of the Allergenic Products Advisory Committee. He was a visiting professor at the National Heart and Lung Institute with Professor Barry Kay in 1994. Dr Grant's research interests have included mechanisms of cellular activation especially the role of chemokines and novel therapies for allergic disorders. Currently he is emphasizing management of difficult patients with urticaria and angioedema. He has authored over 190 publications and chapters and 175 presentations at national and international meetings. Peter Howarth Professor Peter Howarth is Professor of Allergy and Respiratory Medicine and Honorary Consultant Physician within Medicine at the University of Southampton with a clinical and research focus on asthma, particularly severe asthma, and allergy. Professor Howarth has supervised over 20 PhD and DM students (scientists and clinicians) and his research involves Local, National and International collaboration. He has participated in EU funded collaborative programmes, such as BIOAIR and GA2LEN, focusing respectively on severe asthma and allergic diseases, and is joint work package 4 lead for UBIOPRED, the EU/EFPIA funded IMI programme on severe asthma. Professor Howarth has published over 200 peer reviewed papers and lectured extensively at National and International specialist society meetings as an invited speaker. Professor Howarth has contributed to National, European and International (World Health Organisation) guidelines on the management of rhinitis and asthma. He has been on the council of The British Society of Allergy and Clinical Immunology, advisor on allergy to Asthma UK and has been chairman of the board of trustees of Allergy UK. He is currently President of Allergy UK and a trustee of AAIR.

Similar Papers

Research Article
10.1097/aci.0000000000000751

Editorial introductions.

Aug 01, 2021
Current Opinion in Allergy & Clinical Immunology

Editorial introductions.

Front Matter
10.1016/j.jaci.2022.06.026

“Where are they now?” Catching up with the 2017 AAAAI Faculty Development Awardees

Aug 04, 2022
The Journal of Allergy and Clinical Immunology
Zuhair K Ballas

“Where are they now?” Catching up with the 2017 AAAAI Faculty Development Awardees

Research Article
10.1097/aci.0000000000000850

Editorial introductions.

Oct 01, 2022
Current Opinion in Allergy & Clinical Immunology

Editorial introductions.

Research Article
22
10.1186/s13223-015-0087-8

Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants

Aug 03, 2015
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
David M Fleischer + 10 more +10

The purpose of this brief communication is to highlight emerging evidence to existing guidelines regarding potential benefits of supporting early, rather than delayed, peanut introduction during the period of complementary food ntroduction in infants. This document should be considered as interim guidance based on consensus among the following organizations: American Academy of Allergy, Asthma & Immunology; American Academy of Pediatrics; American College of Allergy, Asthma & Immunology; Australasian Society of Clinical Immunology and Allergy; Canadian Society of Allergy and Clinical Immunology; European Academy of Allergy and Clinical Immunology; Israel Association of Allergy and Clinical Immunology; Japanese Society for Allergology; Society for Pediatric Dermatology; and World Allergy Organization. More formal guidelines regarding early-life, complementary feeding practices and the risk of allergy development will follow in the next year from the National Institute of Allergy and Infectious Diseases – sponsored Working Group and the European Academy of Allergy and Clinical Immunology.

Research Article
34
10.1016/j.anai.2015.06.001

Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants

Jun 27, 2015
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
David M Fleischer + 43 more +43

The purpose of this brief communication is to highlight emerging evidence to existing guidelines regarding potential benefits of supporting early, rather than delayed, peanut introduction during the period of complementary food introduction in infants. This document should be considered as interim guidance based on consensus among the following organizations: American Academy of Allergy, Asthma & Immunology, American Academy of Pediatrics, American College of Allergy, Asthma & Immunology, Australasian Society of Clinical Immunology and Allergy, Canadian Society of Allergy and Clinical Immunology, European Academy of Allergy and Clinical Immunology, Israel Association of Allergy and Clinical Immunology, Japanese Society for Allergology, Society for Pediatric Dermatology, and World Allergy Organization. More formal guidelines regarding early-life, complementary feeding practices and the risk of allergy development will follow in the next year from the National Institute of Allergy and Infectious Diseases-sponsored Working Group and the European Academy of Allergy and Clinical Immunology.

Research Article
1
10.3389/conf.fimmu.2013.02.00521

Construction of a naive human phage scFv library and selection, identification of human scFvs

Jan 01, 2013
Frontiers in Immunology
Yuan Qing + 4 more +4

Event Abstract Back to Event Construction of a naive human phage scFv library and selection, identification of human scFvs Qing Yuan1, Siji Nian1*, Xiyuan Guo1, Yan Gao1 and Jiajia Liu1 1 Luzhou medcal college, department of Inmmunology, China The IL-4, IL-13 and IL-33 are key components in the development of allergic disease such as asthma. To construction of human non-immune library and selection of human scFvs against the three cytokines, the mRNA of human peripheral blood cells (PBMC) was extracted from healthy volunteer, and then the cDNA library was constructed. The variable region of heavy chain (VH) and light chain (VL, including Vκ and Vλ) were amplified from full length cDNA library. The VH and VL were ligated with linker and the DNA library of single-chain Fv fragments (scFvs) was developed. After transforming into E.coli TG1, the phage library was constructed. The antigen IL-4, IL-13 and IL-33 were cloned, expressed and identified. The scFv library was enriched for three rounds by phage display for selection of human scFvs against IL-4, IL-13 and IL-33. By PCR, forty two bands of VH, sixteen bands of Vκ and eighteen bands of Vλ were got. And the scFv library was constructed successfully with 2.5x108 development clones with full length scFv inserts. Through three rounds of phage display, 30% clones showed positive using ELISA for detection. Four to five scFvs with high affinity against IL-4, IL-13 and IL-33 respectively were screened, expressed, and identified by Biacore, western blot and sequencing. The results showed the size of proteins of identified scFvs were about 32 kDa and the sequences were correct. The human non-immune library was constructed and the scFvs specific to IL-4, IL-13 and IL-33 respectively were selected successfully. Acknowledgements This work was supported by the Natural Science Foundation of China (No. 31000415) and the project of Science and Technology Department of Sichuan Province (No.2012JQ0018). References ［1］. Moulin, D., Donze, O., Talabot-Ayer, D., Mezin, F., Palmer, G., & Gabay, C. (2007). Cytokine, 40, 216–225. ［2］. Komai-Koma, M., Xu, D., Li, Y., McKenzie, A. N., McInnes, I. B., & Liew, F. Y. (2007). European Journal of Immunology, 37, 2779–2786. ［3］. Suzukawa, M., Iikura, M., Koketsu, R., Nagase, H., Tamura, C., Komiya, A., et al. (2008). Journal of Immunology, 181, 5981–5989. ［4］. Cherry, W. B., Yoon, J., Bartemes, K. R., Iijima, K., & Kita, H. (2008). The Journal of Allergy and Clinical Immunology, 121, 1484–1490. ［5］. Suzukawa, M., Koketsu, R., Iikura, M., Nakae, S., Matsumoto, K., Nagase, H., et al. (2008). Laboratory Investigation, 88, 1245–1253. ［6］. Kondo, Y., Yoshimoto, T., Yasuda, K., Futatsugi-Yumikura, S., Morimoto, M., Hayashi, N., et al. (2008). International Immunology, 20, 791–800. ［7］. Qing, Y., Zhongkang,W., Siji, N., Youping, Y., Gang, C., & Yuxian, X. (2009). Applied Biochemistry and Biotechnology, 152, 224–234. ［8］. Kurowska-Stolarska, M., Kewin, P., Murphy, G., Russo, R. C., Stolarski, B., Garcia, C. C., et al. (2008). Journal of Immunology, 181, 4780–4790. Keywords: Human scFvs, phage display, IL-4, IL-13, IL-33 Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Adaptive Immunity Citation: Yuan Q, Nian S, Guo X, Gao Y and Liu J (2013). Construction of a naive human phage scFv library and selection, identification of human scFvs. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00521 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 07 Jun 2013; Published Online: 22 Aug 2013. * Correspondence: Mr. Siji Nian, Luzhou medcal college, department of Inmmunology, Luzhou, Sichuan province, 646000, China, sijinian@hotmail.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Qing Yuan Siji Nian Xiyuan Guo Yan Gao Jiajia Liu Google Qing Yuan Siji Nian Xiyuan Guo Yan Gao Jiajia Liu Google Scholar Qing Yuan Siji Nian Xiyuan Guo Yan Gao Jiajia Liu PubMed Qing Yuan Siji Nian Xiyuan Guo Yan Gao Jiajia Liu Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.

Research Article
1
10.1007/s42452-025-06553-w

Comparison of research trends and hotspots of DNA and RNA methylation in asthma-related studies based on bibliometric analysis

Feb 22, 2025
Discover Applied Sciences
Junbao Du + 4 more +4

BackgroundAsthma is a prevalent chronic inflammatory disease, and recent research highlights the role of epigenetic modifications, such as DNA and RNA methylation, in its pathogenesis. This study aims to provide a comprehensive bibliometric analysis to evaluate research trends and hotspots in DNA and RNA methylation within asthma-related research.ResultsData were extracted from the Web of Science Core Collection, focusing on English-language publications. Bibliometric tools, including VOSviewer and CiteSpace, were used to analyze publication metrics, author contributions, and keyword trends. The analysis revealed that DNA methylation research in asthma began in 1994 and has shown significant annual growth, while RNA methylation research started a year earlier but with a slightly slower growth trajectory. The United States, China, and the United Kingdom are the leading contributors, with Harvard University being notably influential. Research on DNA methylation has shown higher rates of international collaboration. Despite substantial growth in both areas, recent years have seen a decline in annual publications and citations. The "Journal of Allergy and Clinical Immunology" was identified as the most influential journal in this field. While DNA methylation research is more mature, RNA methylation is gaining prominence, particularly in understanding asthma pathogenesis. Future research should focus on underdeveloped areas, such as "sublingual immunotherapy" and "occupational asthma" for DNA methylation, and "obesity", "lncRNA", "miRNA", "vitamin D", and methylation markers such as "m6A", "m5C", and "m7G" for RNA methylation.ConclusionsThis bibliometric analysis provides a detailed overview of the research landscape in DNA and RNA methylation in asthma. The findings highlight significant growth and collaboration in this field, with specific areas identified for future research. Understanding these trends can help guide future studies and potentially lead to new therapeutic approaches for asthma.

Front Matter
4
10.1016/j.jaci.2021.03.021

The 2021 AAAAI Foundation Faculty Development awardees

Mar 26, 2021
Journal of Allergy and Clinical Immunology
Zuhair K Ballas

The 2021 AAAAI Foundation Faculty Development awardees

Research Article
10
10.1016/j.jaip.2020.05.017

Appointment characteristics in an allergy/immunology practice in the immediate aftermath of COVID-19 restrictions

May 26, 2020
The Journal of Allergy and Clinical Immunology. in Practice
Allison Ramsey + 3 more +3

Appointment characteristics in an allergy/immunology practice in the immediate aftermath of COVID-19 restrictions

Front Matter
13
10.1016/j.jaip.2016.12.031

Rush Venom Immunotherapy: Ready for Prime Time?

May 01, 2017
The Journal of Allergy and Clinical Immunology: In Practice
David B.K Golden

Rush Venom Immunotherapy: Ready for Prime Time?

Research Article
37
10.1111/j.1399-3038.1993.tb00333.x

Modulation of human eosinophil chemotaxis and adhesion by anti-allergic drugs in vitro.

Dec 01, 1993
Pediatric Allergy and Immunology
R Sehmi + 6 more +6

Pediatric Allergy and ImmunologyVolume 4, Issue S4 p. 13-18 Modulation of human eosinophil chemotaxis and adhesion by anti-allergic drugs in vitro R. Sehmi, R. Sehmi Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United KingdomSearch for more papers by this authorG. M. Walsh, G. M. Walsh Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United KingdomSearch for more papers by this authorA. Hartnell, A. Hartnell Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United KingdomSearch for more papers by this authorJ. Barkans, J. Barkans Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United KingdomSearch for more papers by this authorJ. North, J. North Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United KingdomSearch for more papers by this authorA. B. Kay, A. B. Kay Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United KingdomSearch for more papers by this authorR. Moqbel, Corresponding Author R. Moqbel Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United Kingdom*Department of Allergy and Clinical Immunology, National Heart and Lung Institute, Dovehouse St., London SW3 6LY, United KingdomSearch for more papers by this author R. Sehmi, R. Sehmi Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United KingdomSearch for more papers by this authorG. M. Walsh, G. M. Walsh Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United KingdomSearch for more papers by this authorA. Hartnell, A. Hartnell Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United KingdomSearch for more papers by this authorJ. Barkans, J. Barkans Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United KingdomSearch for more papers by this authorJ. North, J. North Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United KingdomSearch for more papers by this authorA. B. Kay, A. B. Kay Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United KingdomSearch for more papers by this authorR. Moqbel, Corresponding Author R. Moqbel Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United Kingdom*Department of Allergy and Clinical Immunology, National Heart and Lung Institute, Dovehouse St., London SW3 6LY, United KingdomSearch for more papers by this author First published: December 1993 https://doi.org/10.1111/j.1399-3038.1993.tb00333.xCitations: 20AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume4, IssueS4December 1993Pages 13-18 RelatedInformation

Research Article
7
10.1161/circresaha.108.173799

The Enigma of Sphingosine 1-Phosphate Synthesis

Mar 28, 2008
Circulation Research
Junsuke Igarashi + 1 more +1

See related article, pages 669–676 Sphingosine 1-phosphate (S1P) is well known as a key sphingolipid messenger molecule in the cardiovascular system, yet many fundamental features of its synthesis, transport, and action remain enigmatic. Indeed, the very name “sphingolipid” was coined to reflect the mysterious characteristics of this class of lipids. It is now well established (through the work of Timothy Hla and of many others subsequently) that S1P binds to and activates a family of G protein–coupled S1P receptors located in vascular endothelial cells, cardiac myocytes, blood platelets, and vascular smooth muscle cells (among other cell types) and elicits a broad range of physiological responses (reviewed elsewhere1). In vascular endothelial cells, S1P elicits such diverse responses as cell survival, proliferation, angiogenesis, cell migration, permeability, and endothelial NO synthase activation. The intracellular signaling pathways stimulated by S1P have been extensively characterized, yet the cellular origins of S1P and the pathways for its transport and action in cardiovascular tissues remain incompletely understood. The concentration of S1P in normal human plasma is within the range of several hundred nanomolar, and this amphipathic lipid is highly protein bound, mostly to HDL and albumin.2 Importantly, S1P receptors bind their ligand with an affinity in the nanomolar range; therefore, many important questions remain. What controls S1P binding to plasma proteins? Where does all this plasma S1P come from? Important clues to the latter question are provided in a recent report from the laboratory of Timothy Hla, published in this issue of Circulation Research 3 and reporting the novel and important discovery: the vascular endothelium is an important source of plasma S1P through the actions of sphingosine kinases (SphKs) in endothelial cells. For many years, conventional wisdom held that blood platelets represent the principal source for S1P in the plasma. Elegant studies by Igarashi …

Front Matter
2
10.4168/aair.2011.3.3.145

Congratulations are due to Allergy, Asthma, & Immunology Research (AAIR) on being listed in Web of Science (SCIE)

Jun 21, 2011
Allergy, Asthma & Immunology Research
Choon-Sik Park

On behalf of the editorial board members, I am honored to announce that AAIR will be listed in SCIE as of June 2011. The inclusion of AAIR in SCIE is not only a first for 2011 among the medical journals published in Korea, but a first among journals on allergy and asthma published in the Asia Pacific region. Indeed, only 18 months have passed since the first issue was published in October 2009. AAIR is published quarterly under the auspices of the Academy of Asthma, Allergy, and Clinical and the Academy of Pediatric Allergy and Respiratory Disease. First, I would like to briefly outline the history of the Academies sponsoring the publication. The Academy of Asthma, Allergy, and Clinical was founded in 1972 and its membership, as of 2011, is comprised of approximately 1200 physicians, pediatricians, rhinologists, and dermatologists. The Academy of Pediatric Allergy and Respiratory Disease was founded in 1987 and consists of 1400 pediatricians in 2011. Since their founding, the two Academies have sponsored several international congresses and symposia on allergy, immunology, and pediatric respiratory diseases. The Korean-Japan Joint Allergy symposium has been held biannually since the founding of the Academy of Asthma, Allergy, and Clinical Immunology. Many international meetings have been hosted successfully in Korea. At international and domestic symposia, members of both Academies have presented numerous excellent abstracts, which have been published in program booklets. Major contributions by Academy members have been published in their official journals: the Korean Journal of Asthma, Allergy, and Clinical Immunology and Korean Journal of Pediatric Allergy and Respiratory Disease. However, as the journals of both Academies are written in and distributed domestically, the results of studies by our members reach few readers outside Korea. To promote international communication by their members, the two Academies decided to publish an official journal in English in 2008. Since it was first issued in Oct 2009, AAIR has presented timely, clinical, basic science and experimental research papers, as well as instructive case reports. As of April 2011, we have published seven issues of AAIR containing five editorials, 26 reviews, 29 original articles, 14 case reports, and one brief communication. Twenty-five world-famous scholars have contributed excellent articles, and 30 domestic professors and researchers have contributed distinguished papers to AAIR. Seventy reviewers have willingly performed their duties for each article, from the title to the last sentence. All of the editorial members would like to express our special appreciation to the authors and reviewers for their outstanding contributions to AAIR. We are keen to develop AAIR as a leading journal in asthma, allergy, and clinical immunology. To enhance its academic quality, we have invited world-class professors and researchers to join the AAIR Advisory and Editorial Boards. As the Editor-in-Chief, I am very grateful for their continuing contributions to AAIR. On behalf of all of the Editors, I look forward to continued excellent support and assistance from members of the Academies. All members have a mission to improve the quality and quantity of AAIR by submitting a variety of clinical and research studies. We also ask the members to cite articles published in AAIR. Finally, preparing the issues of AAIR has been an enjoyable, rewarding experience, which has been greatly enhanced by the contributions of a dedicated team, including the associate editorial members, who are responsible for the final decision on publication for all manuscripts, and a loyal, hard-working Editorial Office staff.

Research Article
10.1111/j.1398-9995.2006.01125.x

And the winner is … 20 years of excellence in research on allergic disease!

Jul 06, 2006
Allergy
M D Chapman

And the winner is … 20 years of excellence in research on allergic disease!

Research Article
2
10.1016/j.waojou.2024.100962

Anaphylaxis in a country where Asia and Europe meet: Evaluation according to World Allergy Organization (WAO) and European Academy of Allergy and Clinical Immunology (EAACI) diagnostic criteria

Sep 01, 2024
World Allergy Organization Journal
İsmet Bulut + 2 more +2

Anaphylaxis in a country where Asia and Europe meet: Evaluation according to World Allergy Organization (WAO) and European Academy of Allergy and Clinical Immunology (EAACI) diagnostic criteria